Welcome to our dedicated page for Celldex Therapeutics news (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics stock.
Celldex Therapeutics Inc. (NASDAQ: CLDX) is a clinical-stage biotechnology company developing antibody-based therapies for mast cell-driven inflammatory and allergic diseases. This page provides centralized access to official press releases, financial disclosures, and third-party analysis of CLDX's progress in advancing treatments for chronic urticarias, atopic dermatitis, and other high-need conditions.
Investors and researchers will find timely updates on clinical trial milestones, regulatory submissions, and strategic collaborations. Content spans Phase 1-3 study results, peer-reviewed research highlights, and management commentary from earnings calls. All materials are sourced directly from Celldex or reputable financial/medical publications.
Key focus areas include developments for lead candidate barzolvolimab (anti-KIT antibody), bispecific antibody CDX-622, and pipeline expansion into new indications. Bookmark this page to monitor progress in mast cell biology innovation without promotional bias.
Celldex Therapeutics (Nasdaq:CLDX) presented promising data on its bispecific platform at the AACR Annual Meeting 2021. The focus was on ILT4 inhibitory monoclonal antibodies for developing bispecific antibodies that counter myeloid cell suppression and activate T-cell responses. Preclinical studies demonstrated the efficacy of these antibodies in enhancing immune response against tumors. The company aims to advance bispecific candidates targeting ILT4 and PD-(L)1, with existing programs such as CDX-527 undergoing clinical trials.
Celldex Therapeutics (NASDAQ:CLDX) reported significant advances in their clinical pipeline during the fourth quarter and year ended December 31, 2020. The Phase 1b study of CDX-0159 in chronic inducible urticaria showed an 80% complete response rate, prompting an expansion to include cholinergic urticaria patients. Financial highlights included a net loss of $21.9 million for Q4 2020, though total revenue increased to $3.8 million, driven by milestone payments. The company maintains a robust cash position with $194.4 million to support operations through 2023.
Celldex Therapeutics (NASDAQ:CLDX) announced interim data from its clinical trial of CDX-0159, aimed at treating antihistamine refractory cold contact urticaria and symptomatic dermographism. Out of 10 patients assessed after treatment, 80% achieved a complete response, indicating a significant efficacy of the drug. CDX-0159 was generally well tolerated, with mild infusion reactions reported. Plans to expand the study to include cholinergic urticaria are underway, and upcoming results from related studies are anticipated.
Celldex Therapeutics (Nasdaq:CLDX) announced its participation in the H.C. Wainwright Global Life Sciences Conference, where a prerecorded fireside chat will be accessible to attendees starting March 9, 2021, at 7:00 a.m. ET. The presentation will be available via webcast on the company's website for fourteen days post-event. Celldex is focused on developing monoclonal and bispecific antibodies aimed at serious diseases, enhancing immune responses, and addressing areas with limited treatment options.
Celldex Therapeutics (Nasdaq: CLDX) announced an expansion of clinical development for CDX-0159 into prurigo nodularis (PN), a chronic skin condition causing intense itch and lesions. The drug, a humanized monoclonal antibody, shows promise by targeting the KIT receptor involved in mast cell activation. CDX-0159 has demonstrated significant plasma tryptase reduction in earlier trials. Celldex aims to initiate the PN study in Q4 2021, responding to a significant unmet medical need as there are currently no FDA-approved therapies for PN, potentially expanding into other itch-driven conditions.
Celldex Therapeutics (Nasdaq: CLDX) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 2:20 p.m. ET. A webcast will be accessible on the 'Events & Presentations' page of the company’s website, with a replay available for 14 days post-event.
Celldex is focused on developing monoclonal and bispecific antibodies to treat serious diseases, aiming to enhance the lives of patients suffering from inflammatory diseases and various cancers.
Celldex Therapeutics, Inc. (Nasdaq:CLDX) has announced the promotion of Freddy A. Jimenez to Senior Vice President and General Counsel, effective January 1, 2021. With over 30 years of experience in the biopharmaceutical industry, Jimenez has significantly contributed to legal strategies supporting the company's R&D and business efforts since joining in 2016. His prior roles include 23 years at Johnson & Johnson, enhancing Celldex's legal compliance and regulatory framework. The leadership change is positioned as crucial for advancing a promising pipeline in 2021.
Celldex Therapeutics (Nasdaq: CLDX) has initiated its open-label clinical trial for CDX-0159, targeting cold contact urticaria and symptomatic dermographism. CDX-0159 is a humanized monoclonal antibody designed to inhibit the KIT receptor, crucial for mast cell activity. The trial aims to assess the drug's safety and clinical efficacy in patients resistant to antihistamines. Preliminary results are expected by Q1 2021. This advancement could address a significant unmet need in a condition affecting 0.5% of the population, positioning CDX-0159 as a potential disease-modifying treatment.
Celldex Therapeutics (NASDAQ:CLDX) will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on December 2 at 4:20 PM ET. A webcast of the presentation will be available on their website, with a replay accessible for 14 days post-event. Celldex focuses on developing monoclonal and bispecific antibodies aimed at treating critical diseases, including inflammatory conditions and various cancers. For detailed information about Celldex's work, visit: www.celldex.com.
Celldex Therapeutics (NASDAQ:CLDX) presented significant updates at the SITC 2020 meeting. Data from the Phase 1 study of CDX-1140, an anti-CD40 monoclonal antibody, highlighted its potential as a best-in-class treatment, showing tumor shrinkage and necrosis in challenging cancer types. The company announced the initiation of expansion cohorts combining CDX-1140 with pembrolizumab and chemotherapy in various cancers. Additionally, CDX-527 and Axl-targeting programs were discussed, indicating ongoing commitment to advancing their innovative therapeutic pipeline.
FAQ
What is the current stock price of Celldex Therapeutics (CLDX)?
What is the market cap of Celldex Therapeutics (CLDX)?
